Translational cancer research is key for addressing, understanding and preventing cancer, a worldwide health concern despite the continuous advancement of research and treatment approaches.
The EU-funded TRANSCAN-3 project is bringing together 31 funding organisations from 20 countries, with the common goal of supporting high-impact translational cancer research. Through cross-national joint calls for proposals and making the most of international and interregional cooperation, TRANSCAN-3 aims to provide influential contributions as well as a sustainable model of funding for ground-breaking translational cancer research in Europe and beyond.
Project Acronym: TRANSCAN-3
Grant Agreement ID: 964264
Title: ERA-NET: Sustained collaboration of national and regional programmes in cancer research
EU Contribution: € 10,949,935.59
Type of action: ERA-NET-Cofund
Overall Budget: € 34,081,623.00
Funding Programme: Horizon 2020 Framework Programme
Duration: 60 months (Mar 2021 – Feb 2026)
Coordinator: Ministero della Salute (Italy)
Consortium: 31 partners
Work Package Structure
TRANSCAN-3 will pursue its specific objectives through the implementation of seven highly-integrated work packages (WP). Four of them with overarching activities (WP1, WP4, WP5 and WP7).
The governance structure of TRANSCAN-3 is shown in the following image. Its governance structure is designed to allow the project to be executed and implemented in an efficient and transparent manner.